---
layout: default
title: Acetaminophen Caffeine
parent: 僅模型預測 (L5)
nav_order: 100
evidence_level: L5
indication_count: 0
---

# Acetaminophen Caffeine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Acetaminophen + Caffeine: Drug Repurposing Candidate Assessment

---

## One-Sentence Summary

Acetaminophen + Caffeine is a fixed-dose analgesic combination in which caffeine acts as an adjuvant to enhance the pain-relieving effect of acetaminophen. The TxGNN model **did not generate any repurposing predictions** for this drug pair in the current pipeline run. This report documents the critical data gaps and outlines the remediation steps required before a full evaluation can be conducted.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no regulatory records retrieved) |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; no supporting studies |
| US Market Status | Not marketed (0 NDA records on file) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## US Market Information

No US market authorizations were retrieved for the combined entity "ACETAMINOPHEN; CAFFEINE." The TFDA query returned 0 results (query ID 1, 2026-03-24). Although both active ingredients are individually available over-the-counter in the United States, no NDA record for this fixed-dose combination was found in the current data pull.

> **Note:** The FDA Orange Book lists numerous acetaminophen + caffeine OTC products (e.g., Excedrin Tension Headache). The absence of records here likely reflects a query-string mismatch or scope limitation of the current data source, and should be verified before drawing conclusions about market status.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN prediction pipeline returned no candidate indications for this combination, and all three critical data layers — regulatory records, mechanism of action, and safety warnings — are absent. A meaningful repurposing evaluation cannot be completed without first resolving these gaps.

**To proceed, the following is needed:**

- **Resolve DrugBank ID:** The DrugBank query returned 1 result (query ID 3) but no DrugBank ID was captured. Confirm and record the canonical ID(s) for acetaminophen (DB00316) and caffeine (DB00201) individually, then re-run the pipeline at component level.
- **Re-run TxGNN at component level:** Combination products are better handled as separate ingredient queries. Run predictions for acetaminophen and caffeine independently.
- **Retrieve MOA data:** Pull mechanism of action from DrugBank API for both components to enable mechanistic plausibility analysis.
- **Obtain package insert warnings:** Download the FDA label PDF and extract key warnings, contraindications, and drug interactions for safety pre-screening.
- **Verify market status:** Cross-check the FDA Orange Book for acetaminophen + caffeine combination products to confirm whether OTC approvals exist and should be included.
- **Clarify candidate intent:** Determine whether the research target is the combination as a unit or one of the individual components; this will determine the correct TxGNN query strategy.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

